Biden's $150M Tech Push to Revolutionize Cancer Surgery

President Joe Biden announced a $150 million funding boost for advanced surgical technology aimed at improving cancer tumor removal. This funding is part of his 'Cancer Moonshot' initiative, with contributions to institutions like Dartmouth and Johns Hopkins. The initiative aims to halve U.S. cancer death rates by 2047.

President Joe Biden announced on Tuesday an allocation of $150 million in new federal funding to develop technology aimed at helping surgeons more effectively remove cancerous tumors. Biden made this announcement during his visit to New Orleans, marking another significant investment in his 'Cancer Moonshot' program. This initiative, led by the President and First Lady, aims to reduce the cancer death rate in the U.S. by at least half by 2047. Nearly two million Americans face a new cancer diagnosis each year, with surgical removal often being the initial treatment step.

Biden emphasized the importance of sharing data and information to fundamentally change the fight against cancer, expressing optimism about the potential for progress. The federal investment seeks to advance next-generation microscopes and imaging technologies to enhance the effectiveness of cancer surgeries, potentially decreasing the need for repeat surgeries and minimizing damage to healthy tissue. Over its first two years, the Biden administration has invested over $400 million to accelerate the prevention, detection, and treatment of cancer.

The recipients of this award include esteemed institutions like Dartmouth College, Johns Hopkins University, and the University of Washington. ARPA-H head Dr. Renee Wegrzyn indicated that additional funding could be released later this winter for further research. Biden's remarks were delivered at Tulane University, where his daughter studied cultural anthropology. Tulane President Michael Fitts noted the university would receive approximately $23 million, stressing that the new technology would revolutionize cancer surgery by enabling surgeons to detect and remove any surrounding cancerous tissue before closing the surgical wound.